Uptake of Oncology Biosimilars: Managed Care Strategies to Improve Value-Based Care Systems

Program Description

The high cost of biologic oncology drugs continues to place significant burden on both patients and the healthcare system. Biosimilars have been developed as alternatives to biologics, with trials proving no meaningful differences in safety, purity, or potency. In recent years, the technologies involved in the development of biosimilars have driven improvements in access to care and treatment while reducing overall healthcare costs. As more biosimilars become available and enter the market, managed care pharmacists must weigh several factors, including the impact of national and state laws, manufacturing considerations, and the potential for improved value-based care stemming from the incorporation of biosimilars into clinical practice. This article will discuss current perspectives and barriers influencing the adoption of oncology biosimilars for formulary inclusion as well as strategies managed care pharmacists can implement to promote the uptake of biosimilars in clinical practice, especially for the treatment of cancer.

Target audience: Managed care pharmacists, oncology pharmacists

Type of activity: Application
Release date: June 29, 2022
Expiration date: June 29, 2023

Time to complete activity: 1.0 hour
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Determine potential economic benefits associated with oncology biosimilars in reducing overall cost of care for patients with cancer.
• Explain the factors considered when evaluating biosimilars for inclusion into formularies and clinical pathways.
• Identify opportunities for improvements in value of care associated with implementation of oncology biosimilars in clinical practice.

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-22-270-H01-P. The activity is available for CE credit through June 29, 2023.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

The following contributors have no relevant financial relationships with commercial interests to disclose:

Faculty

YuQian Liu, PharmD

Medical Writer

Brianna Winters

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Karleen Melody, PharmD; Abigail Dill; Susan Pordon; and Chloe Taccetta.

Pharmacy Times® Editorial Staff—Davy James

Anonymous peer reviewers were used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms